Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
gptkb:drug |
| gptkbp:ATCCode |
N07XX06
|
| gptkbp:CASNumber |
58-46-8
|
| gptkbp:contraindication |
patients with active suicidal ideation
|
| gptkbp:discoveredBy |
Andrzej S. Kostanecki
|
| gptkbp:eliminationHalfLife |
5–8 hours
|
| gptkbp:has_trade_name |
gptkb:Xenazine
|
| gptkbp:hasMolecularFormula |
C19H27NO3
|
| https://www.w3.org/2000/01/rdf-schema#label |
Tetrabenazinum
|
| gptkbp:IUPACName |
(2R,3R,11bR)-3-(2-methylpropyl)-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
VMAT2 inhibitor
|
| gptkbp:meltingPoint |
174–175 °C
|
| gptkbp:metabolism |
liver
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:depression
drowsiness parkinsonism |
| gptkbp:usedFor |
gptkb:Huntington's_disease
chorea |
| gptkbp:bfsParent |
gptkb:tetrabenazine
|
| gptkbp:bfsLayer |
7
|